Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Zimmerli

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Infection|September 19, 2012
Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control studyY Achermann, K Eigenmann, B Ledergerber, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patientsA Cometta, J D Baumgartner, D Lew, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 26, 2019
Pathogenesis and management of fracture-related infectionM Depypere, M Morgenstern, R Kuehl, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 23, 2020
'Pathogenesis and management of fracture-related infection' - Author's replyM Depypere, M Morgenstern, R Kuehl, et al.
Journal of Internal Medicine|December 23, 2014
Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up studyM Alan, E Grolimund, A Kutz, et al.
International Journal of Antimicrobial Agents|April 30, 1999
Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infectionsG Zanetti, S J Harbarth, A Trampuz, et al.
European Journal of Clinical Investigation|September 21, 2000
Disordered calcium homeostasis of sepsis: association with calcitonin precursorsB Müller, K L Becker, M Kränzlin, et al.
Critical Care Medicine|May 25, 2001
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patientsE Abraham, P F Laterre, J Garbino, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Infection|September 19, 2012
Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control studyY Achermann, K Eigenmann, B Ledergerber, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patientsA Cometta, J D Baumgartner, D Lew, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 26, 2019
Pathogenesis and management of fracture-related infectionM Depypere, M Morgenstern, R Kuehl, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 23, 2020
'Pathogenesis and management of fracture-related infection' - Author's replyM Depypere, M Morgenstern, R Kuehl, et al.
Journal of Internal Medicine|December 23, 2014
Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up studyM Alan, E Grolimund, A Kutz, et al.
International Journal of Antimicrobial Agents|April 30, 1999
Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infectionsG Zanetti, S J Harbarth, A Trampuz, et al.
European Journal of Clinical Investigation|September 21, 2000
Disordered calcium homeostasis of sepsis: association with calcitonin precursorsB Müller, K L Becker, M Kränzlin, et al.
Critical Care Medicine|May 25, 2001
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patientsE Abraham, P F Laterre, J Garbino, et al.
Pageof 19